Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARG | P13631 | 14/20 | 1.00 |
| ▸ | RARB | P10826 | 13/20 | 1.00 |
| ▸ | RARA | P10276 | 11/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.67 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | PGR | P06401 | 1/20 | 0.62 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6572485 | 0.89 | RARG (0.80) | RARGRARBRARAMEN1KMT2A | |
| SCHEMBL8766822 | 0.85 | RARB (0.73) | RARGRARBRARAMEN1KMT2A | |
| SCHEMBL6739841 | 0.83 | RARG (1.00) | RARGRARBRARAMEN1KMT2A | |
| SCHEMBL29357613 | 0.83 | RARG (1.00) | RARGRARBRARAMEN1KMT2A | |
| SCHEMBL13980238 | 0.82 | RARB (0.70) | RARGRARBRARAMEN1KMT2A | |
| SCHEMBL30012262 | 0.82 | RARG (1.00) | RARGRARBRARAMEN1KMT2A | |
| SCHEMBL6535556 | 0.82 | RARG (1.00) | RARGRARBRARAMEN1KMT2A | |
| SCHEMBL13687852 | 0.81 | RARB (0.69) | RARGRARBRARAMEN1KMT2A | |
| SCHEMBL8766479 | 0.81 | RARG (1.00) | RARGRARBRARAMEN1KMT2A | |
| SCHEMBL6535828 | 0.81 | RARG (1.00) | RARGRARBRARAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0920312-B1 | APOPTOSIS INDUCING ADAMANTYL DERIVATIVES AND THEIR USAGE AS ANTI-CANCER AGENTS | GALDERMA RES & DEV (FR) | 2004-12-08 | — | — | EP | claimed |
| US-20030073745-A1 | Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents, especially for cervical cancers and dysplasias | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-04-17 | — | — | US | claimed |
| WO-2001056563-A9 | ADAMANTYL DERIVATIVES AS ANTI-CANCER AGENTS | GALDERMA RES & DEV (FR) | 2002-10-31 | — | — | WO | claimed |
| US-6462064-B1 | SUCH AS 6-(3-(1-ADAMANTYL)-4-METHOXYPHENYL)-2-NAPHTHOIC ACID, 2-(3-(1-ADAMANTYL)-4-METHOXYPHENYL)-5-BENZIMIDAZOLE CARBOXY-LIC ACID, AND 6-(3-(1-ADAMANTYL)-4,5-METHYLENEDIOXYPHENYL)-2-NAPHTHOIC ACID | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2002-10-08 | — | — | US | claimed |
| US-6127415-A | ADAMANTYL DERIVATIVE CONTAINING-RETINOID RELATED COMPOUNDS AS ANTICARCINOGENIC AGENTS; SKIN DISORDERS;COSMETICS; AGING RESISTANCE; ALOPEIA | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2000-10-03 | — | — | US | claimed |
| EP-0584191-B1 | NOVEL AROMATIC AND POLYCYCLIC COMPOUNDS AND THEIR USE IN HUMAN OR VETERINARY MEDICINE AND IN COSMETICS | CIRD GALDERMA (FR) | 1997-08-13 | — | — | EP | claimed |
| EP-0584191-A1 | NOVEL AROMATIC AND POLYCYCLIC COMPOUNDS AND THEIR USE IN HUMAN OR VETERINARY MEDECINE AND IN COSMETICS. | CIRD GALDERMA (FR) | 1994-03-02 | — | — | EP | claimed |
| WO-1992019583-A1 | NOVEL AROMATIC AND POLYCYCLIC COMPOUNDS AND THEIR USE IN HUMAN OR VETERINARY MEDECINE AND IN COSMETICS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1992-11-12 | — | — | WO | claimed |
| EP-0920312-B1 | APOPTOSIS INDUCING ADAMANTYL DERIVATIVES AND THEIR USAGE AS ANTI-CANCER AGENTS | GALDERMA RES & DEV (FR) | 2004-12-08 | — | — | EP | disclosed |
| EP-0584191-B1 | NOVEL AROMATIC AND POLYCYCLIC COMPOUNDS AND THEIR USE IN HUMAN OR VETERINARY MEDICINE AND IN COSMETICS | CIRD GALDERMA (FR) | 1997-08-13 | — | — | EP | disclosed |
| US-5547983-A | Aromatic and polycyclic compounds and their use in human or veterinary medicine and in cosmetics | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1996-08-20 | — | — | US | disclosed |
| EP-0584191-A1 | NOVEL AROMATIC AND POLYCYCLIC COMPOUNDS AND THEIR USE IN HUMAN OR VETERINARY MEDECINE AND IN COSMETICS. | CIRD GALDERMA (FR) | 1994-03-02 | — | — | EP | disclosed |
| WO-1992019583-A1 | NOVEL AROMATIC AND POLYCYCLIC COMPOUNDS AND THEIR USE IN HUMAN OR VETERINARY MEDECINE AND IN COSMETICS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1992-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073745-A1 | Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents, especially for cervical cancers and dysplasias | CASP3, BAD, RARA | RARG 14/4885RARB 10/4885RARA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.